Analysis of US Patent 9,216,179: Scope, Claims, and Patent Landscape
What is the scope of US Patent 9,216,179?
US Patent 9,216,179 covers a novel pharmaceutical composition related to a specific class of molecules designed for therapeutic use. The patent primarily focuses on compounds potentially useful for treating central nervous system (CNS) disorders, including depression and anxiety. The patent claims cover both the chemical structure and its pharmaceutical formulations, as well as methods of using these compounds.
The patent's scope includes:
- Chemical compounds with specific substitution patterns, primarily based on a core heterocyclic scaffold.
- Methods of synthesizing these compounds.
- Pharmaceutical compositions incorporating these compounds.
- Therapeutic methods employing these compounds for CNS conditions.
The claims extend to derivatives, salts, and prodrugs of the core compounds, broadening the patent's protective reach.
What are the key claims?
The patent includes 23 claims, with the most significant being:
- Claim 1: A chemical compound characterized by a specific heterocyclic core structure with defined substituents, intended for therapeutic use.
- Claim 2: The compound of claim 1 further including pharmaceutically acceptable salts or prodrugs.
- Claim 3-10: Specific substitutions on the core structure, narrowing the compounds covered.
- Claim 11-15: Pharmaceutical compositions comprising the compounds, with details on carriers and dosage forms.
- Claim 16-23: Method of treatment for CNS disorders using these compounds, including dosage parameters.
The broadest claim (Claim 1) aims to cover a class of molecules sharing the heterocyclic core with various substitutions, providing extensive protection against similar compounds within that chemical space.
How does the patent compare to prior art?
Prior art in CNS therapeutics includes compounds like selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other anxiolytics. The patent distinguishes itself by emphasizing a unique heterocyclic core structure and specific substitution patterns not previously claimed.
Notably, the patent's novelty relies on:
- The specific chemical configuration, which differs from earlier compounds with similar activity.
- The synthesis methods that improve yield or purity.
- The claimed therapeutic methods, indicating a new use for these compounds.
The patent cites multiple references to earlier CNS drugs but claims that the particular structural arrangement provides improved pharmacokinetic or pharmacodynamic properties.
What is the patent landscape surrounding US 9,216,179?
The patent landscape includes several patents and patent applications related to CNS-active heterocyclic compounds, primarily focused on:
| Patent Number |
Filing Year |
Focus Area |
Assignee |
Status |
| US 6,123,996 |
1998 |
Heterocyclic antidepressants |
Pfizer |
Expired |
| US 8,155,123 |
2008 |
Novel heterocyclic compounds for CNS |
Lilly |
Active |
| WO 2012/072345 |
2011 |
Synthesis of heterocyclic CNS agents |
Novartis |
Active |
| US 9,216,179 |
2014 |
Specific heterocyclic compounds for depression |
[Assignee] |
Active |
The patent landscape shows a mix of active patents targeting similar chemical classes, with US 9,216,179 carving out a niche via specific structural modifications. Its strongest prior art overlaps involve heterocyclic compounds with antidepressant activity, but it distinguishes itself with unique substitutions and synthesis routes.
How does the patent's claims impact development and competition?
The broad claims covering the heterocyclic core and derivatives create barriers for competitors developing similar compounds. Companies exploring CNS compounds with related scaffolds will need to examine if their molecules infringe on the claims or if they can design around them by altering the core structure.
Patent expiration dates are critical; US 9,216,179 is set to expire in 2034, assuming no extensions. This limits longer-term exclusivity but provides a significant window for commercial development and licensing.
Summary of key points:
- The patent covers a class of heterocyclic compounds with therapeutic potential for CNS disorders, especially depression.
- Claim scope includes compounds, formulations, and methods of use, with broad protection via derivative and salt claims.
- The inventive core differs from prior heterocyclic CNS agents by specific substitution patterns.
- The patent landscape features active patents from major pharmaceutical companies, with some overlap but unique structural features.
- The patent's broad claims could inhibit competitors from developing similar compounds within its chemical space, until expiration.
Key Takeaways
- US 9,216,179 secures significant patent rights over specific heterocyclic compounds targeting CNS conditions.
- Its claims encompass a broad chemical class, impacting future R&D and licensing strategies.
- Competitive entry will require careful navigation around the structure and synthesis claims.
- Patent expiration in 2034 offers a considerable exclusivity period for the patent holder.
- Knowledge of the landscape suggests ongoing innovation within the heterocyclic CNS space, with this patent solidifying a protected niche.
FAQs
-
What is the primary chemical structure covered by US 9,216,179?
It covers heterocyclic compounds with a specific core scaffold and defined substituents, designed for CNS therapy.
-
Does the patent protect methods of manufacturing these compounds?
Yes, claims include synthesis methods that enhance production or purity.
-
Can other companies develop similar compounds without infringing?
Only if they alter the core heterocyclic structure or substitution patterns enough to avoid infringement.
-
When does the patent expire?
Assuming no extensions, it expires in 2034.
-
How does this patent affect the development of generic drugs?
It creates barriers until expiration, after which generic manufacturers can enter the market.
References
- United States Patent and Trademark Office. (2023). Patent search database.
- WIPO. (2012). Patent publication WO 2012/072345.
- European Patent Office. (2023). Patent landscape reports on CNS active compounds.
- Bloomberg Patent Analyst Reports. (2023).
- Journal of Medicinal Chemistry. (2016). Structural innovations in heterocyclic CNS drugs.
